Lilly’s Retatrutide Outperforms Ozempic in Diabetes Study
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Eli Lilly said its investigational triple-G drug retatrutide lowered blood sugar and reduced body weight more effectively than Novo Nordisk’s Ozempic in a large head-to-head study involving people with diabetes.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu